Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AEterna Zentaris, a biopharmaceutical company focused on endocrine therapy and oncology, has completed the transaction under the previously announced purchase and sale agreement with Cowen Healthcare Royalty Partners, relating to AEterna Zentaris's rights to royalties on future sales of Cetrotide covered by its license agreement with Merck Serono.
Subscribe to our email newsletter
AEterna Zentaris has received $52.5 million from Cowen Healthcare Royalty Partners (CHRP) at closing, less certain transaction costs. Under the terms of the agreement with CHRP, AEterna Zentaris would receive an additional payment of $2.5 million from CHRP contingent on 2010 net sales of Cetrotide reaching a specified level.
Cetrotide (cetrorelix) was the first luteinizing hormone-releasing hormone antagonist treatment approved for in vitro fertilization. It is administered to women to prevent premature ovulation in order to increase fertility success rate.